Table 3.
Analysis of recurrence and mortality as binary outcomes on the overall population and according to intrinsic subtype. Statistically significant associations are shown in bold. Only genes/signatures with significant unadjusted P values for at least one outcome are shown. APM, antigen processing machinery; BRCA, Breast Cancer gene; FDR, false‐discovery rate; HER2, human epidermal growth factor receptor‐2; IDO1, indoleamine 2,3‐dioxygenase‐1; PD‐1, programmed death‐1; PD‐L1, programmed death‐ligand‐1; PD‐L2, programmed death‐ligand‐2; PGR, progesterone receptor; SD, standard deviation; TIGIT, T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibition motif domains; TIS, tumor inflammation signature.
| Recurrence | Mortality | |||||
|---|---|---|---|---|---|---|
| Mean (SD) score | P‐value | Mean (SD) score | P‐value | |||
| Patients with event | Patients without event | Patients with event | Patients without event | |||
| Overall (N = 141) | ||||||
| PD‐L1 | −3.38 (0.92) | −2.90 (1.05) | 0.005 | −3.30 (0.94) | −3.00 (1.06) | 0.074 |
| PD‐L2 | −3.67 (0.92) | −3.32 (0.88) | 0.022 | −3.56 (0.86) | −3.44 (0.96) | 0.435 |
| CD8+ T‐cells | −2.54 (0.97) | −2.18 (1.04) | 0.037 | −2.53 (0.96) | −2.20 (1.05) | 0.048 |
| Cytotoxic cells | −3.62 (0.94) | −3.27 (1.06) | 0.039 | −3.58 (0.95) | −3.33 (1.05) | 0.131 |
| Inflammatory chemokines | 4.31 (1.29) | 4.53 (1.09) | 0.280 | 4.21 (1.22) | 4.62 (1.14) | 0.037 |
| Luminal A (N = 49) | ||||||
| Basal | −0.42 (0.29) | −0.57 (0.20) | 0.031 a | −0.42 (0.29) | −0.57 (0.30) | 0.132 |
| p53 | 4.28 (0.84) | 3.74 (0.77) | 0.028 | 4.28 (0.84) | 3.74 (0.79) | 0.028 |
| Differentiation | 5.17 (0.73) | 5.58 (0.90) | 0.006 | 5.17 (0.73) | 5.58 (0.90) | 0.056 |
| BRCAness | 4.75 (0.76) | 4.43 (0.57) | 0.013 | 4.75 (0.76) | 4.43 (0.77) | 0.099 |
| Luminal B (N = 39) | ||||||
| PGR | −1.59 (2.47) | −0.59 (1.58) | 0.242 | −1.90 (2.37) | −0.28 (1.61) | 0.015 a |
| Inflammatory chemokines | 3.78 (0.90) | 4.50 (0.65) | 0.012 | 3.88 (0.85) | 4.26 (0.92) | 0.196 |
| HER2‐enriched (N = 27) | ||||||
| Inflammatory chemokines | 3.67 (1.39) | 4.50 (1.28) | 0.120 | 3.52 (1.39) | 4.69 (1.10) | 0.025 |
| Basal‐like (N = 26) | ||||||
| TIS | 6.99 (0.80) | 8.39 (0.62) | <0.001 a , b | 7.18 (0.81) | 8.32 (0.84) | 0.002 a , b |
| IDO1 | −1.99 (1.12) | 0.12 (1.63) | 0.001 b | −1.96 (1.19) | 0.25 (1.55) | <0.001 a , b |
| PD‐L1 | −3.24 (0.86) | −1.86 (0.70) | <0.001 a , b | −3.04 (0.98) | −1.95 (0.81) | 0.005 a , b |
| PD‐L2 | −3.48 (0.90) | −2.66 (0.96) | 0.036 | −3.41 (0.87) | −2.67 (1.03) | 0.060 |
| TIGIT | −3.49 (0.93) | −2.35 (0.90) | 0.004 b | −3.32 (0.96) | −2.44 (1.02) | 0.033 |
| CD8+ T‐cells | −2.38 (0.50) | −1.45 (0.81) | 0.002 b | −2.34 (0.55) | −1.41 (0.79) | 0.002 a , b |
| Cytotoxic cells | −3.59 (0.85) | −2.39 (0.69) | 0.001 a , b | −3.38 (0.77) | −2.51 (0.98) | 0.018 |
| APM | 5.66 (1.15) | 6.70 (0.89) | 0.016 | 5.79 (1.15) | 6.64 (0.97) | 0.055 |
| Cytotoxicity | 5.09 (1.55) | 6.50 (1.40) | 0.022 | 5.28 (1.59) | 6.43 (1.46) | 0.067 |
| PD‐1 | −4.70 (1.09) | −3.20 (0.85) | 0.001 a , b | −4.50 (1.11) | −3.29 (1.03) | 0.009 a |
Multiple logistic regression adjusted for intrinsic subtype (overall population only), age (< 43 versus ≥ 43 years), pT stage (T1 versus T2 versus T3 versus T4), and number of involved nodes (4–9 versus > 9).
P‐value < 0.05 following FDR correction.